-
Next-Generation
Oncology TherapeuticsTransforming Biomedical Ideas Into Therapeutic Innovation
-
Transforming today's ideation into tomorrow's therapeutic innovation.
Pioneering Targeted
Protein DegradationTransforming Biomedical Ideas Into Therapeutic Innovation
Transforming today's ideation into tomorrow's therapeutic innovation.
About Us
Basanti BioMedical is an early-stage biomedical startup founded in 2023 to bridge the critical gap between scientific discovery and real-world therapeutic implementation. We are focused on delivering next-generation oncology degraders with early evidence of efficacy in varied types of cancers systems, targeting diseases where conventional approaches have shown limited success.
Proprietary Linker Platform
Our indigenous innovative linker platform enhances the activity of the PROTAC by selective targeting, cell permeability and formation of ternary complex. We have optimized the length, group, type, flexibility and the conjugation site of the linker to increase the PROTAC efficiency.
In-House and CRO-Enabled Execution
Building our oncology discovery program through both in-house capabilities and CRO partnerships to accelerate preclinical validation with scientific rigour.
- In-vitro experiment and target validation underway
- Patent applications in progress
- Bootstrapped and founder-led with focused research execution
This philosophy guides everything we do at Basanti BioMedical. We pursue the deepest questions in cancer biology with scientific discipline and the belief that transformative answers are within reach.
Advancing Targeted Oncology from India
Our Focus Areas
Designing and developing first-in-class anticancer molecules targeting key oncogenic pathways, with demonstrated preclinical evidence of efficacy in varied types of cancers systems.
Developing a proprietary, India-originated linker platform that enables precise intracellular targeting — the backbone of our multifunctional therapeutic architecture.
Engineering Proteolysis Targeting Chimeras (PROTACs) that harness the cell’s own ubiquitin-proteasome system to selectively degrade disease-causing proteins in cancer cells.
Why choose us
Why Basanti BioMedical Is Different
We combine rigorous scientific thinking with a startup’s agility. Our proprietary technology addresses the core challenges in oncology drug delivery — selectivity, efficacy, and safety — through an innovative molecular architecture built from the ground up in India.
Selective Mechanism of Action
Our degrader platform is designed for precision, binding exclusively to cancer cells while minimising harm to healthy tissue, addressing one of oncology's most critical challenges.
Patent-Protected Innovation
Patent applications are in-process covering both our novel linker platform and our proprietary therapeutic molecule, protecting a genuinely differentiated scientific approach.
Cancer Indications Targeted
R&D experiment underway
Patent Applications In Progress
Years of Research Focus
Our Research Process
From Concept to Therapeutic Candidate in Four Steps
Scientific Ideation
Identifying unmet needs in hard-to-treat cancers and designing novel molecular strategies around varied types of cancers.
Design & Synthesis
Engineering our proprietary multifunctional linker platform and synthesising the therapeutic candidate for evaluation.